1Christ W,Lehnert T,Uibrich B.Specific toxicologic ofects of the Quindones[J].Rev Infect Dis,1988,10(1):S141-S146.
2Schliiter G.Cproftoxacin:review of potential toxicologic effects[J].Am J Med,1987,826(Suppl.4A):91-93.
3Schaad UB,Salam MA,Aujard Y,et al.Vse of fluoroguindones in pediatrics:consensus reportof on internatonod societg of chemotherapy Commission[J].Pediatr Infect Dis J,1995,14(1):1-9.
4Mayer DG.Overview of toxicological srudies[J].Drugs,1987.34(Suppt):150-153.
6Schaad UB,Stoupic C,Wedgwood KJ,et al.Clinical radiologic andmagnetic resonance monitoring for skeletal toxicity in pediatric patients withcystic fibrosis receiving a threemonth course of ciprofloxacin[J].Pediatr lnfect Dis J,1991,10:723-729.
7Lumbiganon P,Pengsaa K,Sookpranee T.Ciprofloxacin in neonates and its possible adverse effect on the teeth[J].Pediatr lnfect Dis J,1991,10:619-620.
8Wessalowski R,Thomas L,Livit J,et al.Multiple brain abscess caused bysalmonella enteritidis in a neonate:successful treatment with ciprofloxacin[J].Pediatr lnfect Dia J,1993,12:683-688.
9Lang R,Goshen S,Roas RA,et al.Oral ciprofloxacin in the management of chronic suppurative otitis media without cholesteatoma in children:preliminary experience in 21 children[J].Pediatr Infect Dis J,1992,11:925-929.
10Schaad UB.Use of fluorquinolones in pediatrics:consensus report of intemational society of chemotherapy commission[J].Pediatr Infect Dis J,1995,14:1-9.
3Clinical and Laboratory Standards Institute (CLSI).Performance standards for antimicrobial susceptibility testing,18th informational supplement.M100 S18.PA:Wayne,2008.
4Grisaru-Soen G,Sweed Y,Lerner-Geva L,et al.Nosocomial bloodstream infections in a pediatric intensive care unit:3-year survey.Med Sci Monit,2007,13:CR251CR257.
5Klevens RM,Morrison MA,Nadle J,et al.Invasive methicillin-resistant Staphylococcus aureus infections in the United States.JAMA,2007,298:1763-1771.
